Independent health research notes · Education only · Not medical advice
Subscribe
Hormones · Peer-reviewed

The case for early HRT — and the studies that quietly buried the WHI.

Timing, symptom burden, bone density, risk stratification, and why menopause medicine still argues with a 2002 headline.

Peer-reviewedBy The Glow Diary editorial desk · Last reviewed 21 Apr 2026 · 10 min read
The case for early HRT — and the studies that quietly buried the WHI.

Hormone therapy is not one thing. Route, dose, age, time since menopause, uterus status, clot risk, breast-cancer history, and symptom burden all change the conversation.

The timing hypothesis

The post-WHI era forced a necessary caution, but it also created a generation of simplistic fear. For many symptomatic, appropriately screened women near menopause, the risk-benefit picture can be materially different from the headline version.

The Glow call

This is clinician territory. The best HRT conversations look boring: personal history, labs when useful, clear goals, follow-up, and a willingness to stop or adjust.

Medical note

This review is for education only and is not medical advice. Treatment decisions should be made with a licensed clinician who knows your history, medications, labs, and goals.